Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Decreases By 28.7%

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 50,200 shares, a decrease of 28.7% from the November 30th total of 70,400 shares. Currently, 9.4% of the company’s shares are short sold. Based on an average daily trading volume, of 273,900 shares, the days-to-cover ratio is presently 0.2 days.

Bone Biologics Price Performance

Shares of BBLG stock remained flat at $0.95 during trading hours on Friday. 203,428 shares of the stock traded hands, compared to its average volume of 1,372,615. The business’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.46. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $10.56.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.